Pharmacokinetics of crizotinib in NSCLC patients

Bibliography

• MSoda, YLChoi, MEnomoto, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6
   PubMed Web of Science ®Google Scholar
• REShackelford, MVora, KMayhall, et al. ALK-rearrangements and testing methods in non-small cell lung cancer: a review. Genes Cancer 2014;5:1-14
   PubMedGoogle Scholar
• SPerner, PLWagner, FDemichelis, et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 2008;10:298-302
   PubMed Web of Science ®Google Scholar
• JJCui, MTran-Dubé, HShen, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011;54:6342-63
   PubMed Web of Science ®Google Scholar
• BSolomon, KDWilner, ATShaw. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Clin Pharmacol Ther 2014;95:15-23
   PubMed Web of Science ®Google Scholar
• HXu, MO’Gorman, TBoutros, et al. Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects. J Clin Pharmacol 2015;55(1):104-13
   PubMed Web of Science ®Google Scholar
• ATShaw, DWKim, KNakagawa, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94
   PubMed Web of Science ®Google Scholar
• XZhang, SZhang, XYang, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010;9:188
   PubMed Web of Science ®Google Scholar
• ATShaw, JAEngelman. ALK in lung cancer: past, present, and future. J Clin Oncol 2013;31:1105-11
   PubMed Web of Science ®Google Scholar
• SMMalik, VEMaher, KEBijwaard, et al. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res 2014;20:2029-34
   PubMed Web of Science ®Google Scholar
• AJWeickhardt, DLAisner, WAFranklin, et al. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer 2013;119:1467
   PubMed Web of Science ®Google Scholar
• ELKwak, YJBang, DRCamidge, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703
   PubMed Web of Science ®Google Scholar
• GToyokawa, TSeto. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer? Clin Lung Cancer 2014;15:313-19
   PubMed Web of Science ®Google Scholar
• DKazandjian, GMBlumenthal, HYChen, et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist 2014;19:e5-e11
   PubMed Web of Science ®Google Scholar
• HQian, FGao, HWang, et al. The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials. BMC Cancer 2014;14:683
   PubMed Web of Science ®Google Scholar
• DBCosta, SKobayashi, SSPandya, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011;29:e443-5
   PubMed Web of Science ®Google Scholar
• DMaillet, IMartel-Lafay, DArpin, MPérol. Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement. J Thorac Oncol 2013;8:e30
   PubMed Web of Science ®Google Scholar
• SYamazaki. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib. AAPS J 2013;15:354-66
   PubMed Web of Science ®Google Scholar
• SYamazaki, PVicini, ZShen, et al. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. J Pharmacol Exp Ther 2012;340:549-57
   PubMed Web of Science ®Google Scholar
• CLi, CAlvey, ABello, et al. Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J Clin Oncol 2011;29(Suppl):abstr. e13065
   Google Scholar
• Food and Drug Administration. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2011/202570s000lbl.pdf
   Google Scholar
• EMEA report. Available from: www.ema.europa.eu/WC500134761.pdf
   Google Scholar
• JEFrampton. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs 2013;73:2031-51
   PubMed Web of Science ®Google Scholar
• TRJohnson, WTan, LGoulet, et al. Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects. Xenobiotica 2014;18:1-15
   Google Scholar
• ATimm, JMKolesar. Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm 2013;70:943-7
   PubMed Web of Science ®Google Scholar
• YPMossé, MSLim, SDVoss, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol 2013;14:472-80
   PubMed Web of Science ®Google Scholar
• WJZhou, XZhang, CCheng, et al. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. Br J Pharmacol 2012;166:1669-83
   PubMed Web of Science ®Google Scholar
• LLandi. Cappuzzo. Management of NSCLC: focus on crizotinib. Expert Opin Pharmacother 2014;10:1-11
   Google Scholar
• TEStinchcombe. Novel agents in development for advanced non-small cell lung cancer. Ther Adv Med Oncol 2014;6(5):240-53
   PubMed Web of Science ®Google Scholar
• DFHeigener, MReck. Crizotinib. Recent Results Cancer Res 2014;201:197-205
   PubMedGoogle Scholar
• KEsfahani, JSAgulnik, VCohen. A Systemic review of resistance mechanisms and ongoing clinical trials in alk-rearranged non-small cell lung cancer. Front Oncol 2014;4:174
   Google Scholar
• DRCamidge, WPao, LVSequist. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 2014;11:473-81
   PubMed Web of Science ®Google Scholar
• YHKim, HOzasa, HNagai, et al. High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. J Thorac Oncol 2013;8:e85-6
   PubMed Web of Science ®Google Scholar
• DIacono, RChiari, GMetro, et al. Future options for ALK-positive non-small cell lung cancer. Lung Cancer 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• SChuan Tang, LNNguyen, RWSparidans, et al. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer 2014;134:1484-94
   PubMed Web of Science ®Google Scholar
• NMiyajima, STsutsumi, CSourbier, et al. The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. Cancer Res 2013;73(23):7022-33
   PubMed Web of Science ®Google Scholar
• LYang, GLi, LZhao, et al. Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive non-small cell lung cancer. Tumour Biol 2014;35(10):9759-67
   PubMed Web of Science ®Google Scholar
• CRolfo, GSortino, ESmits, et al. Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer? Expert Rev Anticancer Ther 2014;14(10):1173-87
   PubMed Web of Science ®Google Scholar